Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Must have received: standard-of-care therapy — refractory or intolerant, or no standard treatment exists

AST refractory to or intolerant of available standard-of-care therapy or for which no standard treatment exists

Cannot have received: systemic cancer therapy

Any investigational or approved systemic cancer therapy (including chemotherapy, immunotherapy, hormonal therapy and herbal/alternative therapies with anti-cancer indications, or targeted therapy) administered within 28 days or 5 half-lives, whichever is shorter, before the first dose of study drug

Cannot have received: treatment targeting the ATR/CHK1 pathway

Any treatment targeting the ATR/CHK1 pathway

Cannot have received: live virus or bacterial vaccine

Exception: non-live COVID-19 vaccines allowed

Live virus or bacterial vaccine within 28 days prior to the first dose of study drug and whilst the patient is receiving study drug. Patients who require COVID-19 vaccination whilst on study drug should receive a non-live vaccine (e.g., one based on messenger RNA (mRNA) or fully inactivated/genetically modified viruses incapable of replication)

Cannot have received: investigational product

Participation in another clinical study with an investigational product administered in the last 28 days or 5 half-lives (whichever is shorter) prior to the first administration of study drug

Cannot have received: investigational device

An investigational device within 28 days prior to the first dose of study drug

Cannot have received: proton pump inhibitors or potassium competitive acid blockers

Patients who may need continuous treatment with proton pump inhibitors or potassium competitive acid blockers during the study period

Cannot have received: major surgery

Patients who have undergone a major surgery or have undergone a radical radiotherapy within 28 days prior to the first dose of study drug or have undergone a palliative radiotherapy within 14 days prior to the first dose of study drug, or have used a radioactive drug (Strontium, Samarium, etc.) within 56 days prior to first dose of study drug